HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 7,453-7,464 of 27,277
Drug study icon
TerminatedNCT00965419

Pediatric people with Attention Deficit/Hyperactivity Disorder

What is this study about?

Researchers are studying Edivoxetine, tracking side effects to assess long-term safety and tolerability in children with ADHD.

This study ended early.

Multiple locations, including Spring Valley
ADHDMedication studyAges 6–18
Countries
United States, Canada, Taiwan
Sponsor
Eli Lilly and Company
Drug study icon
CompletedNCT00922636

Pediatric people with Attention Deficit/Hyperactivity Disorder

What is this study about?

Researchers compared LY2216684, methylphenidate and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.

This study has finished and is no longer accepting participants.

Multiple locations, including Spring Valley
ADHDMedication studyAges 6–17
Countries
United States, Canada
Sponsor
Eli Lilly and Company
Drug study icon
TerminatedNCT00977522

PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

Official study title

A Randomized Phase 2, Double-Blind, Placebo-Controlled, Multi-Center Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia Treated With A Stable Dose Of A Second Generation Antipsychotic

This study ended early.

Multiple locations, including Cerritos
SchizophreniaMedication studyAges 18–55
Countries
United States
Sponsor
Pfizer
Other study type icon
CompletedNCT03615794

Pregnant and Postpartum Women With and Without Mood Disorders

Official study title

A Prospective Study of Pregnant and Postpartum Women With and Without Mood Disorders

This study has finished and is no longer accepting participants.

Multiple locations, including Baltimore
Depression, Bipolarity, ...Observational studyAges 18–50
Countries
United States
Sponsor
Johns Hopkins University
Drug study icon
CompletedNCT03866174

Psilocybin for Major Depressive Disorder (MDD)

Official study title

A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)

This study has finished and is no longer accepting participants.

Multiple locations, including San Francisco
DepressionMedication studyAges 21–65
Countries
United States
Sponsor
Usona Institute
Drug study icon
Active Not RecruitingNCT06407635

Psilocybin for PTSD

Official study title

Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy

This study is no longer accepting new participants.

In Baltimore
PTSDMedication studyAges 21–75
Countries
United States
Sponsor
Johns Hopkins University
Behavioral study icon
CompletedACTRN12621001097831

Psilocybin-assisted psychotherapy for treatment-resistant depression

What is this study about?

This study evaluated the effectiveness of psychotherapy for people with depression.

This study has finished and is no longer accepting participants.

In Australia
DepressionInterventional studyAges 18–65
Countries
Australia
Sponsor
Swinburne University of Technology
Drug study icon
CompletedNCT00791622

QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine

Official study title

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating QT/QTc Intervals Following Administration of Extended-release Paliperidone and Quetiapine in Subjects With Schizophrenia or Schizoaffective Disorder

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–50
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00791349

QT and QTc Intervals in Patients Administered Immediate Release Paliperidone

Official study title

A Placebo- and Positive-controlled, Randomized Study Evaluating QT and QTc Intervals Following Administration of Immediate-release Paliperidone in Subjects With Schizophrenia or Schizoaffective Disorder

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–50
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
TerminatedNCT03352453

Rapastinel for depression

What is this study about?

Researchers are comparing Rapastinel and placebo to find out how the approaches affect depression symptoms in adults with depression.

This study ended early.

Multiple locations, including Birmingham
Depression, SuicidalityMedication studyAges 18–65
Countries
United States
Sponsor
Naurex, Inc, an affiliate of Allergan plc

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.